Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Kissei

Status and phase: Completed; Phase 2

Conditions: Spinocerebellar Degeneration

Treatments: Drug: KPS-0373

Study type: Interventional

Funder types: Industry

Identifiers

NCT00863538

KPS1201

Details and patient eligibility

About

To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD

Enrollment: 40 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• SCD with mild to moderate ataxia

Exclusion criteria

• Patients with secondary ataxia
• Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

1

Experimental group

Treatment:

Drug: KPS-0373